BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31667337)

  • 1. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.
    Hasan MK; Widhopf GF; Zhang S; Lam SM; Shen Z; Briggs SP; Parker BA; Kipps TJ
    NPJ Breast Cancer; 2019; 5():35. PubMed ID: 31667337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
    Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
    Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Yu J; Chen L; Chen Y; Hasan MK; Ghia EM; Zhang L; Wu R; Rassenti LZ; Widhopf GF; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2608-2614. PubMed ID: 28465528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
    Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
    Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
    Choi MY; Widhopf GF; Ghia EM; Kidwell RL; Hasan MK; Yu J; Rassenti LZ; Chen L; Chen Y; Pittman E; Pu M; Messer K; Prussak CE; Castro JE; Jamieson C; Kipps TJ
    Cell Stem Cell; 2018 Jun; 22(6):951-959.e3. PubMed ID: 29859176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells.
    Wu X; Yan T; Hao L; Zhu Y
    Cancer Manag Res; 2019; 11():2803-2815. PubMed ID: 31114334
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
    Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.
    Hasan K; Kipps TJ
    Oncotarget; 2023 Mar; 14():207-209. PubMed ID: 36944183
    [No Abstract]   [Full Text] [Related]  

  • 12. Wnt5a/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells.
    Dai B; Shen Y; Yan T; Zhang A
    Oncol Rep; 2020 Feb; 43(2):601-608. PubMed ID: 31894282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
    Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
    Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
    [No Abstract]   [Full Text] [Related]  

  • 14. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma.
    Yu J; Chen Y; Chen L; Zhang L; Rassenti LZ; Widhopf GF; Kipps TJ
    Oncotarget; 2018 May; 9(37):24731-24736. PubMed ID: 29872501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
    Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
    Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rho family small GTPase Rif regulates Wnt5a-Ror1-Dvl2 signaling and promotes lung adenocarcinoma progression.
    Nishita M; Kamizaki K; Hoshi K; Aruga K; Nishikaku I; Shibuya H; Matsumoto K; Minami Y
    J Biol Chem; 2023 Oct; 299(10):105248. PubMed ID: 37703992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility.
    Wang W; Liu Y; Liao K
    BMC Cell Biol; 2011 Nov; 12():49. PubMed ID: 22078467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
    Zhang S; Chen L; Cui B; Chuang HY; Yu J; Wang-Rodriguez J; Tang L; Chen G; Basak GW; Kipps TJ
    PLoS One; 2012; 7(3):e31127. PubMed ID: 22403610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
    Chen Y; Chen L; Yu J; Ghia EM; Choi MY; Zhang L; Zhang S; Sanchez-Lopez E; Widhopf GF; Messer K; Rassenti LZ; Jamieson C; Kipps TJ
    Blood; 2019 Sep; 134(13):1084-1094. PubMed ID: 31409670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.